Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220059 | 0.90 | KMT2A (0.72) | TSHRKDM4EHSD17B10KMT2AMEN1 | |
| SCHEMBL19221685 | 0.86 | HTT (0.72) | TSHRKDM4EHSD17B10KMT2AMEN1 | |
| SCHEMBL1835415 | 0.85 | KMT2A (0.66) | TSHRKDM4EHSD17B10KMT2AMEN1 | |
| SCHEMBL14855770 | 0.80 | KCNA5 (0.65) | TSHRKDM4EHSD17B10KMT2AMEN1 | |
| SCHEMBL14855684 | 0.80 | TSHR (1.00) | TSHRKDM4EHSD17B10KMT2AALDH1A1 | |
| SCHEMBL14855966 | 0.80 | POLB (0.64) | KMT2AMEN1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL530857 | 0.80 | KMT2A (0.68) | TSHRKDM4EHSD17B10KMT2AMEN1 | |
| SCHEMBL2058331 | 0.79 | ALDH1A1 (0.68) | KMT2AMEN1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL1638701 | 0.79 | ALDH1A1 (0.62) | TSHRKDM4EHSD17B10KMT2AMEN1 | |
| SCHEMBL12863710 | 0.78 | MEN1 (0.64) | TSHRKDM4EHSD17B10KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2580190-A1 | NEW ANTIVIRAL COMPOUNDS | Wadell, Göran (SE) | 2013-04-17 | — | — | EP | claimed |
| WO-2011155898-A1 | NEW ANTIVIRAL COMPOUNDS | WADELL GOERAN (SE) | 2011-12-15 | — | — | WO | claimed |
| US-8993622-B2 | Antiviral compounds | EIRIUM AB (SE) | 2015-03-31 | — | — | US | disclosed |
| US-8993622-B2 | Antiviral compounds | EIRIUM AB (SE) | 2015-03-31 | — | — | US | disclosed |
| US-8993622-B2 | Antiviral compounds | EIRIUM AB (SE) | 2015-03-31 | — | — | US | disclosed |
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | EIRIUM AB (SE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | EIRIUM AB (SE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | EIRIUM AB (SE) | 2013-08-15 | — | — | US | disclosed |
| EP-2580190-A1 | NEW ANTIVIRAL COMPOUNDS | Wadell, Göran (SE) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011155898-A1 | NEW ANTIVIRAL COMPOUNDS | WADELL GOERAN (SE) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210915-A1 | ANTIVIRAL COMPOUNDS | MAVS, ZC3HAV1, EIF2AK2 | TSHR 4873/4885KDM4E 2866/4885HSD17B10 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.